EMA Authorised: Evrenzo (roxadustat) — Astellas Pharma Europe B.V.

View source ↗

Summary

EMA authorised Evrenzo (roxadustat) for the treatment of anemia associated with chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• EVRENZO (roxadustat)

Snippet

Status: Authorised. Therapeutic area: Anemia;Kidney Failure, Chronic. MAH: Astellas Pharma Europe B.V.. Decision date: 30/03/2026